USPTO Allows MDRNA Patent on Peptides for Delivery to Lung | GenomeWeb

MDRNA said this week that the US Patent and Trademark Office has allowed a company patent application covering "methods for the delivery of a broad array of compounds with pharmacological activity, including siRNAs, using proprietary targeting peptides that have preferential binding affinity for lung tissue."

The application, No. 20070197444, is entitled, "Phage-Displayed Cell-Binding Peptides," and claims "a tryptophan cage-binding domain polypeptide containing of all or part of [a defined] amino acid sequence," according to its abstract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.